{
    "Trade/Device Name(s)": [
        "ARCHITECT 2nd Generation Testosterone"
    ],
    "Submitter Information": "Abbott Laboratories Diagnostics Division",
    "510(k) Number": "K152155",
    "Predicate Device Reference 510(k) Number(s)": [
        "K120009"
    ],
    "Regulatory Class": "Class I, Reserved",
    "Product Code(s)": [
        "CDZ"
    ],
    "Summary Letter Date": "November 13, 2015",
    "Summary Letter Received Date": "November 16, 2015",
    "Submission Date": "December 14, 2015",
    "Regulation Number(s)": [
        "21 CFR 862.1680"
    ],
    "Regulation Name(s)": [
        "Testosterone test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Testosterone"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT i System"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent microparticle immunoassay (CMIA)"
    ],
    "Methodologies": [
        "Immunoassay",
        "Delayed one-step immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for ARCHITECT 2nd Generation Testosterone assay, a CMIA for quantitative measurement of testosterone in serum and plasma, including updated labeling for Free Testosterone Index (FTI/FAI) values.",
    "Indications for Use Summary": "Quantitative determination of testosterone in human serum and plasma to aid in diagnosis and treatment of disorders involving androgens, including hypogonadism, puberty disorders, impotence in males, and hirsutism or virilization in females.",
    "fda_folder": "Clinical Chemistry"
}